Arturi F, Chiefari E, Tumino S, Russo D, Squatrito S, Chazenbalk G, Persani L, Rapoport B, Filetti S
Department of Experimental and Clinical Medicine, University of Catanzaro Magna Graecia, Italy.
J Endocrinol Invest. 2002 Sep;25(8):696-701. doi: 10.1007/BF03345103.
Constitutively activating germline mutations of the TSH receptor (TSH-R) are considered the cause of hereditary non-autoimmune hyperthyroidism. In this study, 10 members (8 affected and 2 unaffected) of an Italian family with hereditary non-autoimmune hyperthyroidism were investigated for the presence of mutations in the TSH-R gene. The clinical features of the disease were also analyzed. PCR-amplified fragments of the TSH-R gene were obtained from genomic DNA extracted from peripheral blood leukocytes of each family member and analyzed by direct nucleotide sequencing and restriction analysis. An identical germline TSH-R mutation was detected in all the patients with hyperthyroidism but in none of the unaffected family members. The mutation was heterozygotic and determined the substitution of valine for methionine (codon 463; ATG-->GTG) in the second transmembrane domain of the TSH-R. When expressed in chinese hamster ovary (CHO) cells, the Val463 mutant TSH-R induced constitutive activation of the TSH receptor. Analysis of the clinical features of our family and those of other families with hereditary non-autoimmune hyperthyroidism, including one with the same Val463 mutation, revealed wide variability in the phenotypical expression of the disease. Our findings indicate that an activating germline mutation in the TSH-R gene plays a key role in hereditary non-autoimmune hyperthyroidism although the onset of clinical manifestations and the evolution of the disease seem to depend heavily on other factors, thus far unidentified. The absence of a clear correlation between mutant genotypes and phenotypic expression of the disease currently limits the prognostic value of genetic testing in families with hereditary non-autoimmune hyperthyroidism.
促甲状腺激素受体(TSH-R)的组成型激活种系突变被认为是遗传性非自身免疫性甲状腺功能亢进症的病因。在本研究中,对一个患有遗传性非自身免疫性甲状腺功能亢进症的意大利家族的10名成员(8名患者和2名未患病者)进行了TSH-R基因突变检测。同时分析了该疾病的临床特征。从每个家族成员外周血白细胞提取的基因组DNA中获得TSH-R基因的PCR扩增片段,并通过直接核苷酸测序和限制性分析进行分析。在所有甲状腺功能亢进症患者中均检测到相同的种系TSH-R突变,而在未患病的家族成员中均未检测到。该突变是杂合性的,导致TSH-R第二个跨膜结构域中的甲硫氨酸被缬氨酸取代(密码子463;ATG→GTG)。当在中国仓鼠卵巢(CHO)细胞中表达时,Val463突变型TSH-R诱导TSH受体的组成型激活。对我们家族以及其他患有遗传性非自身免疫性甲状腺功能亢进症家族(包括一个具有相同Val463突变的家族)的临床特征分析显示,该疾病的表型表达存在很大差异。我们的研究结果表明,TSH-R基因中的激活种系突变在遗传性非自身免疫性甲状腺功能亢进症中起关键作用,尽管临床表现的发作和疾病的演变似乎在很大程度上取决于其他尚未明确的因素。目前,突变基因型与疾病表型表达之间缺乏明确的相关性,这限制了遗传性非自身免疫性甲状腺功能亢进症家族中基因检测的预后价值。